December 17, 2014
SAN FRANCISCO – According to preliminary data presented at the ASH Annual Meeting and Exposition, FLT3 inhibitors have been shown to have a dramatic, positive effect on patients with acute myeloid leukemia and their chance of survival.
“FLT3 inhibitors can inhibit the activity of FLT3 dramatically after transplantation,” Edward A. Copelan, MD, FACP, chair of the department of hematologic oncology and blood disorders at Levine Cancer Institute told HemOnc Today. “There is a hint that survival is improved by this and the survival curves looked excellent. So in this respect, identifying patients in small subsets of AML, and this is probably 25% of patients, and treating them in a unique way seems to improve survival and offer substantial progress for the future.”